Compare ResMed Inc. (RMD) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Teucrium Wheat Fund — how do they compare? ResMed Inc. trades at $230.12 (market cap $31.89B), while Teucrium Wheat Fund trades at $24.43 (market cap $273.67M). The key difference: ResMed Inc. is far larger — about 116.5× Teucrium Wheat Fund's market cap, and ResMed Inc. pays a 1.16% dividend while Teucrium Wheat Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Teucrium Wheat Fund for 40 Days on average.
| RMD | WEAT | |
|---|---|---|
Market Cap | $31.89B | $273.67M |
Volume | 618,314 | 222,576 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $277.88 | $28.00 |
52-Week Low | $182.82 | $19.88 |
Typical Hold Time | 51 Days | 40 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
WEAT trades at $24.9, down 2.31% over the past day amid a bearish technical signal from moving averages. The stock's technical indicators show neutral oscillators but selling pressure from the ADX. Recent news highlights WEAT's strong performance earlier in the year, with a 25% year-to-date gain as of July 2026, though inflation concerns persist as a market-wide theme.
The outlook for WEAT is cautious due to bearish technical momentum and macroeconomic headwinds from inflation. Investment opportunity exists if the stock holds key support levels, but risks include continued selling pressure and sensitivity to broader economic conditions. Investors should weigh technical weakness against the fund's earlier 2026 gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
